Celecoxib targets breast cancer stem cells by inhibiting the synthesis of prostaglandin E(2) and down-regulating the Wnt pathway activity

Pharmacological targeting of breast cancer stem cells (CSCs) is highly promising for the treatment of breast cancer, as the small population of CSCs is responsible for tumor initiation, progression, recurrence and chemo-resistance. Celecoxib is one of the most commonly used non-steroidal anti-inflam...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Chaolin, Chen, Yuanhong, Liu, Hang, Yang, Jing, Song, Xuejing, Zhao, Junping, He, Na, Zhou, Chengji J., Wang, Yongping, Huang, Changjiang, Dong, Qiaoxiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5777769/
https://www.ncbi.nlm.nih.gov/pubmed/29383157
http://dx.doi.org/10.18632/oncotarget.23250

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5777769/
https://www.ncbi.nlm.nih.gov/pubmed/29383157
http://dx.doi.org/10.18632/oncotarget.23250

Ejemplares similares